Login to Your Account

IDEC Licenses Cancer Molecule; Early Rituxan RA Data Unveiled

By Randall Osborne

Wednesday, October 2, 2002
IDEC Pharmaceuticals Corp. licensed a small-molecule cancer drug from Japan and the company's chief financial officer resigned, but analysts seemed just as interested - if not more - in a third bit of news not formally disclosed by the company: an abstract showing how well Rituxan (rituximab) worked against rheumatoid arthritis in Phase II trials. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription